Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LENZ LENZ Therapeutics	$34.68 +8.0%	$31.26	$16.53 ▼ $38.93	$989.14M	0.42	384,565 shs	1.14 million shs
NRIX Nurix Therapeutics	$9.84 -2.3%	$11.86	$8.18 ▼ $29.56	$752.26M	2.14	805,329 shs	523,459 shs
SLRN Acelyrin	$2.27	$2.27	$1.85 ▼ $7.10	$229.17M	1.07	1.29 million shs	N/A
URGN Urogen Pharma	$17.75 -4.5%	$14.05	$3.42 ▼ $21.01	$819.84M	1.12	1.34 million shs	1.18 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LENZ LENZ Therapeutics	0.00%	+15.75%	+1.23%	+31.66%	+49.55%
NRIX Nurix Therapeutics	0.00%	-10.87%	-22.34%	+3.58%	-50.82%
SLRN Acelyrin	0.00%	0.00%	0.00%	-3.81%	-54.05%
URGN Urogen Pharma	0.00%	-8.51%	+21.24%	+71.50%	+22.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LENZ LENZ Therapeutics	1.6483 of 5 stars	3.6	0.0	0.0	0.0	3.7	0.8	0.0
NRIX Nurix Therapeutics	2.5197 of 5 stars	4.4	1.0	0.0	0.0	3.2	0.8	0.0
SLRN Acelyrin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	4.5953 of 5 stars	4.5	4.0	0.0	4.5	2.1	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LENZ LENZ Therapeutics	3.17	Buy	$49.60	43.02% Upside
NRIX Nurix Therapeutics	2.81	Moderate Buy	$28.87	193.36% Upside
SLRN Acelyrin	2.40	Hold	$9.60	322.91% Upside
URGN Urogen Pharma	3.00	Buy	$32.86	85.11% Upside

Current Analyst Ratings Breakdown

Latest SLRN, LENZ, NRIX, and URGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/31/2025	LENZ LENZ Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $49.00
7/31/2025	LENZ LENZ Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$39.00 ➝ $40.00
7/31/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/28/2025	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$38.00 ➝ $48.00
7/15/2025	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$17.00 ➝ $16.00
7/14/2025	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
7/10/2025	NRIX Nurix Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $26.00
7/10/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/10/2025	NRIX Nurix Therapeutics	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00
7/8/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	$7.24 per share	N/A
NRIX Nurix Therapeutics	$54.55M	13.79	N/A	N/A	$7.44 per share	1.32
SLRN Acelyrin	N/A	N/A	N/A	N/A	$6.74 per share	N/A
URGN Urogen Pharma	$91.87M	8.93	N/A	N/A	($0.21) per share	-84.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LENZ LENZ Therapeutics	-$49.77M	-$1.90	N/A	N/A	N/A	N/A	-25.63%	-24.43%	8/13/2025 (Estimated)
NRIX Nurix Therapeutics	-$193.57M	-$2.61	N/A	N/A	N/A	-234.57%	-45.26%	-34.71%	10/10/2025 (Estimated)
SLRN Acelyrin	-$381.64M	-$2.69	N/A	N/A	N/A	N/A	-44.12%	-39.02%	8/12/2025 (Estimated)
URGN Urogen Pharma	-$126.87M	-$3.32	N/A	N/A	N/A	-164.44%	-97,487.15%	-55.66%	N/A

Latest SLRN, LENZ, NRIX, and URGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	LENZ LENZ Therapeutics	-$0.62	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	SLRN Acelyrin	-$0.71	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	URGN Urogen Pharma	-$0.85	-$1.05	-$0.20	-$1.05	$23.06 million	$24.22 million
7/30/2025	Q2 2025	LENZ LENZ Therapeutics	-$0.58	-$0.53	+$0.05	-$0.53	$5.00 million	$5.00 million
7/9/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.79	-$0.52	+$0.27	-$0.52	$16.26 million	$44,056.00 billion
5/14/2025	Q1 2025	SLRN Acelyrin	-$0.95	-$0.55	+$0.40	-$0.55	N/A	N/A
5/12/2025	Q1 2025	URGN Urogen Pharma	-$0.83	-$0.92	-$0.09	-$0.92	$22.71 million	$20.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
SLRN Acelyrin	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LENZ LENZ Therapeutics	N/A	20.54	20.54
NRIX Nurix Therapeutics	N/A	6.82	6.82
SLRN Acelyrin	N/A	7.15	7.15
URGN Urogen Pharma	N/A	5.65	5.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LENZ LENZ Therapeutics	54.32%
NRIX Nurix Therapeutics	N/A
SLRN Acelyrin	87.31%
URGN Urogen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
LENZ LENZ Therapeutics	6.90%
NRIX Nurix Therapeutics	7.40%
SLRN Acelyrin	13.60%
URGN Urogen Pharma	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LENZ LENZ Therapeutics	110	28.52 million	26.55 million	N/A
NRIX Nurix Therapeutics	300	76.45 million	70.79 million	Optionable
SLRN Acelyrin	135	100.95 million	86.68 million	Optionable
URGN Urogen Pharma	200	46.20 million	44.03 million	Optionable

SLRN, LENZ, NRIX, and URGN Headlines

Recent News About These Companies

UroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call Transcript

August 9 at 4:01 AM | seekingalpha.com

UroGen Pharma Ltd. 2025 Q2 - Results - Earnings Call Presentation

August 9 at 3:06 AM | seekingalpha.com

Urogen Pharma (NASDAQ:URGN) Stock Price Down 14.4% on Disappointing Earnings

August 9 at 2:07 AM | americanbankingnews.com

Urogen Pharma (NASDAQ:URGN) Stock Price Down 14.4% Following Weak Earnings

August 8 at 11:22 AM | marketbeat.com

UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ...

August 8 at 7:41 AM | finance.yahoo.com

UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI

August 8 at 2:30 AM | tipranks.com

UroGen (URGN) Q2 Revenue Rises 11%

August 7 at 12:52 AM | aol.comA

UroGen (URGN) Q2 Revenue Rises 11%

August 7 at 12:52 AM | aol.comA

UroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beat

August 7 at 12:52 AM | investing.com

UroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beat

August 7 at 12:52 AM | investing.com

Urogen Pharma’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Tara Bancroft

August 7 at 2:45 PM | tipranks.com

Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates

August 7 at 10:16 AM | zacks.com

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

August 7 at 8:00 AM | globenewswire.com

UroGen Pharma Q2 2025 Earnings Preview

August 6, 2025 | msn.com

D. Boral Capital Reaffirms Buy Rating for Urogen Pharma (NASDAQ:URGN)

August 6, 2025 | marketbeat.com

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade ...

August 6, 2025 | finance.yahoo.com

Urogen Pharma (NASDAQ:URGN) Sets New 1-Year High - Should You Buy?

August 5, 2025 | marketbeat.com

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

August 5, 2025 | globenewswire.com

Privium Fund Management B.V. Has $1.19 Million Stock Position in Urogen Pharma (NASDAQ:URGN)

August 3, 2025 | marketbeat.com

Jefferies Financial Group Inc. Lowers Holdings in Urogen Pharma (NASDAQ:URGN)

August 1, 2025 | marketbeat.com

Mark Schoenberg Sells 5,149 Shares of Urogen Pharma (NASDAQ:URGN) Stock

July 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLRN, LENZ, NRIX, and URGN Company Descriptions

LENZ Therapeutics NASDAQ:LENZ

$34.68 +2.56 (+7.97%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$36.57 +1.89 (+5.45%)

As of 08/8/2025 07:59 PM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Nurix Therapeutics NASDAQ:NRIX

$9.84 -0.23 (-2.28%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$10.07 +0.23 (+2.39%)

As of 08/8/2025 06:56 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Acelyrin NASDAQ:SLRN

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Urogen Pharma NASDAQ:URGN

$17.75 -0.84 (-4.52%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$17.95 +0.20 (+1.15%)

As of 08/8/2025 07:29 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time